Background: In previous studies, we observed decreased neuronal and increased astrocyte
Introduction
Although neuronal loss and synapse dysfunction are the preceding events of cognitive deficits in Alzheimer's disease (AD), neurons do not work or survive by themselves. These delicate organelles require supports through intimate collaborations within themselves and with other cell types 1 . The microenvironment of cellular crosstalk, interaction, balance, and circuits maintained by neurons, astrocytes, microglia, oligodendrocytes, and other vascular cells are essential for the brain to carry out functions and fight against insults.
AD associated risk factors identified across the genome also point to the involvements of multi-cell types apart from neurons 1, 2 . APOE4 is related to lipid metabolism and mostly expressed in astrocyte and microglia 3 . Other lipid metabolism related risk genes are ABCA7 identified in all cell types 2, 4 , CLU in astrocyte and oligodendrocyte precursor cells 2, 5, 6 , and SORL1 in astrocyte 2 . Research interests in the roles of inflammatory response to toxic stimuli or microbial infection have been escalating recently, and AD risk genes associated with immune response including TREM2 [7] [8] [9] , PLCG2 9 , ABI3 9 , CR1 2, 6 , CD33 2, 4 , HLA-DRB5-HLA-DRB1 2 , and
INPP5D
2 are mostly expressed in microglia and macrophages. BIN1 expressed in microglia, oligodendrocyte, and neurons 2 , and PICALM expressed in microglia and endothelial cells 2, 5 are associated with endocytosis.
In a normal functional brain, astrocytes, microglia, and oligodendrocytes provide trophic supports to neurons and various cell type specific functions. Astrocytes confer multiple functions to fulfill neurons' metabolic needs 10 including but not limited to providing substrates for oxidative phosphorylation 11 , exerting regulation of excitatory CNS neurotransmitter glutamate 12, 13 , and serving as bidirectional communication nodes that talk to both neurons and blood vessels and modulate their activities in an arrangement of functional entities named neurovascular units [14] [15] [16] . Microglia surveil in the extracellular space and look for pathogens or debris to engulf through phagocytosis. Oligodendrocyte provides insulation to neurons by wrapping around the axons with myelin sheath. However, in an AD diseased brain, these supporting cells may become double-edged swords that play beneficial and/or harmful roles as disease progresses. Amyloid-β accumulation and clearance are the central events of the amyloid cascade hypothesis. Both astrocyte and microglia have been involved in response to the toxic stimuli of amyloid plaques. During the early stage, microglia [17] [18] [19] and astrocytes 19-21 accumulate around plaques to phagocytose or degrade those in a protective manner. However, as disease progresses, the chronic and prolonged activation of microglia and astrocytes will be provoked into a damaging pro-inflammatory state and a vicious circle that exacerbate pathology in a harmful manner. Evidence suggested that increased inflammatory cytokine secretion in microglia, and increased production of complement cascade components, and impaired glutamate regulation (unregulated glutamate activity can cause neuronal excitatory cell death) 13 may contribute to synaptic loss which ultimately leads to cognitive deficits. Disrupted neuronal plasticity due to myelin loss and dysfunctional neurovascular units further exacerbate the dreadful situation and destroy the harmony of the multi-cell type microenvironment.
Apart from disturbed homeostatic processes and impaired circuits integrity, cell type composition or proportion is also altered. Brains affected by AD exhibits neuronal loss, oligodendrocyte loss, astrocytosis, and microgliosis. However, the specific effects that pathological mutations and risk variants have on brain cellular composition are often ignored. To investigate the changes of cerebral cortex cell-type population structure and account for the associated confounding effects in downstream analysis, we developed an in-silico deconvolution method to infer cellular composition from RNA-Seq data, which has been documented in our previous publication 22 . In summary, we firstly assembled a reference panel to model the transcriptomic signature of neurons, astrocytes, oligodendrocytes and microglia. The panel was created by analyzing expression data from purified cell lines. We evaluated various digital deconvolution methods and selected the best performing ones for our primary analyses. We tested the digital deconvolution accuracy on induced pluripotent stem cell (iPSC) derived neurons and microglia, and neurons derived from Translating Ribosome Affinity Purification followed by RNA-Seq. Finally, we verified its accuracy with simulated admixture with predefined cellular proportions.
Once the deconvolution approach was optimized, we calculated the cell proportion in AD cases and controls from different brain regions of LOAD and ADAD datasets. We found that neuronal and astrocyte relative proportions differ between healthy and diseased brains, and also 
Methods

Study participants
The participants were sourced from seven studies with a total sample size of 1,669
( Table 1) Table 1 . To compare with the neurodegenerative disorders, we also included schizophrenia (N = 210) and bipolar disorders (N = 34) participants from the CommonMind study ( 
Data collection and generation
Cortical tissues from various locations of post-mortal brains were collected ( 37 were used for phasing and imputation. Individual genotypes imputed with probability < 0.90 were set to missing and imputed genotypes with probability ≥0.90 were analyzed as fully observed. Genotyped and imputed variants with MAF < 0.02 or IMPUTE2 information score < 0.30 were excluded. WGS data quality is censored by filtering out reads with sequencing depth DP < 6 and quality GQ < 20 followed by similar QC approaches as described above for genotyping data. After the QC, all studies including imputed genotype and WGS data was merged into a binary file using Plink for downstream analysis. PCA and IBD analyses were performed on the merged binary files using Plink to keep European ancestry and unrelated participants ( Figure 1 and Figure 2 ).
Expression Data
FastQC was applied to RNAseq data to examine various aspects of sequencing quality 38 .
Outlier samples with high rRNA contents or low sequencing depth were removed from the pool.
The remaining samples were aligned to human GRCh37 primary assembly using Star with 2-Pass Basic mode (ver 2.5.4b) 39 . Alignment metrics were ascertained by applying Picard For the final merging phase, both discovery and replication studies were combined to maximize sample size. Apart from meta-tissue analysis by each tissue of each study, a split by disease status analysis was also performed in the final merging phase. Samples from each tissue of each study were also split into disease categories. Resultant subcategory with less than 20 subjects were removed from the analysis to avoid false results due to too small sample size.
Similar data preparation and analysis pipeline were enforced as documented above.
QTL analysis results were uploaded to Fuma (v1.3.3d) 49 to annotation significant SNPs (p-value < 10 -06 ) with GWAScatalog (e91_r2018-02-06) and ANNOVAR (updated 2017-07-17).
Gene-based analysis was also performed by Magma (v1.06) 50 implemented in Fuma. According to the data request terms, DIAN data are available upon request: http://dian.wustl.edu
Data availability
Results
Study Design
The ROSMAP study containing 523 subjects will be the discovery dataset, and the other six studies are collapsed into replication dataset with 1,146 subjects. Altogether, we have assembled a set of cortical RNA-Seq data comprised of 1,669 participants predominantly focused on neurodegenerative disorders from seven sources (Figure 4 , Table 1 GTEx also included multiple tissue data, which were collected from multiple regions of the same subjects that allow us to perform region specific comparison within the same cohort.
Discovery analysis was performed in ROSMAP study. In the replication phase, all the other studies were merged to replicate signals identified from the discovery ROSMAP set.
Because GTEx and MSSM contain multiple cortical regions collected from the same subjects, we also applied meta-tissue software 47 specifically designed for multi-tissue QTL analysis to perform a mixed model analysis with random effects that account for correlated measurements from multi-tissue individuals. To attain the largest available sample size for this study, the discovery and replication sets were merged to perform the merged multi-tissue QTL analysis in a search for additional signals hidden in previously separated discovery or replication analysis due to lack of power. After merged analysis, the cohorts were split into four major disease status groups (AD, control, schizophrenia, other non-AD neurodegenerative disorders) to explore how different disease strata could impact the results.
TMEM106B variants associated with neuronal proportion
During discovery phase, ROSMAP dataset (N = 484 after removing outliers from total number of 523 subjects) was used to perform cell type proportion QTL analysis. Using normalized neuronal proportion as a quantitative trait, the QTL analysis identified more than 10 peaks that passed genome wide suggestive threshold (<1.0×10 -06 , Figure 5AB , Table 3 ).
However, only one signal rs1990621 (chr7: 12283873) were replicated with p-value = 7.41×10
-04
in the replication dataset (N = 1,052) combining all the other datasets except ROSMAP ( Figure   5CD ). When the discovery and replication datasets were merged to attained a larger sample size (N = 1,536), rs1990621 major allele C is negatively associated with neuronal proportion with pvalue = 9.42×10 -09 ( Figure 6AB, Figure 7AC ), which means the minor allele G is associated with increased neuronal proportion in our assembled datasets focusing on neurodegenerative disorders.
Noticeably, in both replication and merged analyses, multi-tissue data were involved that provided additional power but also posed challenges to the analysis, the same issue faced by the GTEx study 34, 51 . Compared to a tissue-by-tissue approach, multiple tissues collected from the same subject may help identify QTL by aggregating evidence from multiple tissues, which is similar to a meta-analysis of combining each study. However, one violation of such approach is that the tissues collected from the same subject are presumably highly correlated since they shared the same genetic architecture. Thus, it violates the assumption of independency for carrying out a standard meta-analysis 47 . Regarding the effect heterogeneity, Meta-Tissue calculated a m-value 48 to predict if a variant has an effect in a tissue. M-value is similar to the posterior probability of association based on the Bayes factor 48 but with differences specifically designed for detecting whether an effect is present in a study included in a meta-analysis. Figure 7B is a PM-Plot that integrates evidences from both frequentist (p-value) and Bayesian (m-value) sides to interpret the heterogeneity of multi-tissue QTL effects. Variant rs1990621 in ROSMAP and Mayo studies have m-values greater than 0.9, are predicted to have an effect and color coded with red. In CMC study, the mvalue is less than 0.1, so it is predicted to not to have an effect and color coded with blue. All the other studies with m-value between 0.1 and 0.9 are predicted with ambiguous effect and color coded with green. Based on the forest plot and PM-Plot, the variant does have effect heterogeneity across different tissues and studies. In this case, random-effect model will be more suitable to account for effect heterogeneity. Therefore, summary random effect and p-value were reported for the analysis.
Apart from multi-tissue QTL, a single-tissue joint analysis was also performed. In this case, one tissue region was drawn from the multi-tissue data to avoid violating the independency assumption. Specifically, BM36 and frontal cortex tissue were selected to represent MSSM and GTEx study respectively. Study sites were coded as dummy variables to account for potential batch effects. In this joint analysis, the variant rs1990621 is also the top hit with p-value = 7.66×10 -10 .
Neuronal protective effect of TMEM106B variants observed in neurodegenerative disorders and normal aging participants
To explore the effect in different disease categories, the merged dataset was stratified based on disease: AD, other non-AD neurodegenerative disorders, schizophrenia and control.
Signification associations between rs1990621 and neuronal proportion were observed in AD (p- Figure 7D ). The effect of the variant was more prominent in neurodegenerative cohorts and aging controls with mean age of death greater than 65 years old.
However, it was absent from younger cohorts such as GTEx controls and CommonMind schizophrenia participants. Thus, this variant seems to be associated with a neuronal protection mechanism shared by any aging process in the present or absence of neuropathology.
Functional annotation
The variant rs1990621 is located in the TMEM106B gene region where other variants in high LD linkage are also located and labeled in Figure 8A . Although the CADD score and RegulomeDB score for this variant are not remarkably high to suggest any functional consequences ( Figure 8BC ), this variant is in high LD with rs1990622 (r 2 = 0.98), a TMEM106B variant previous identified to be associated with FTD risk 25 , particularly in granulin precursor (GRN) mutation carriers 52, 53 . TMEM106B is expressed in neurons and microglia, with highest protein expression detected in the late endosome/lysosome compartments of neurons [54] [55] [56] [57] . A nonsynonymous variant rs3173615, which is also in high LD with rs1990621 (r 2 = 0.98), located in the exon 6 of TMEM106B (the dark blue dot in Figure 8B ) produces two protein isoforms (p.T185S) that affect TMEM106B protein level through protein degradation mechanism 55, 58, 59 .
The impact of other neurodegenerative risk loci on neuronal proportion
To investigate what other AD or FTD variants might have an effect in neuronal proportion QTL analysis, we extracted results for 38 SNPs examined in two large scale genome wide association studies, AD focused (Lambert et al. 2 ) and FTD focused (Ferrari et al. 60 ) studies.
Among those, only variants located in TMEM106B and APOE gene regions passed genome wide significant or suggestive threshold. Both rs1990622 ( Figure 9A ) and rs2075650 ( Figure 9B) were found to be associated with FTD reported in Ferrari et al., which were associated with neuronal proportion in this study ( Table 5) . The top signals in APOE region are rs283815, rs769449, and rs429358 with p-value < 1.22×10 -05 . Note that rs429358 is one of the two SNPs that determine APOE isoforms. Remember that APOE e4 alleles, coded by rs429358(C) and rs7412(C), confers the largest effect for AD risk. We observed that the C allele of rs429358 was associated with decreased neuronal proportion, but no association observed between rs7412 and neuronal proportion.
In a gene-based analysis of our neuronal proportion QTL, TMEM106B (p-value = 2.96×10 -08 ) is the only gene that passed genome-wide significant threshold followed by APOE (p-value = 3.2×10 -05 ), the most important gene for sporadic AD risk ( Figure 6CD ). Previous
GWAS for AD risk performed with the International Genomics of Alzheimer's Project (IGAP)
data stratified by APOE genotype showed that AD risk is significantly influenced by the interaction between APOE and TMEM106B 61 . Together with our observation of cellular composition QTL, these results suggest a potential interaction of TMEM106B and APOE may play a role in affecting AD risk/vulnerability and cellular composition balance between neurons and astrocytes, and the endosome and lysosome compartments might be the location that the interaction takes place.
Discussion
The common variant rs1990622 in TMEM106B was first identified to be associated with 55, 58, 59 . TMEM106B overexpression results in enlarged lysosomes and lysosomal dysfunction 55, 71 . It has also been shown that TMEM106B may interact with PGRN (the precursor protein for granulin) in lysosome 59 . Although rs3173615 is not included in our genomic data, it is in complete linkage disequilibrium with rs1990621 and rs1990622. It is worth pointing out that the minor allele of rs1990622, which has a protective effect in FTD, is in-phase with the minor allele of rs1990621, which is associated with increased neuronal proportion in our analysis.
Despite the fact that our dataset is focused on neurodegeneration, we only have 11 verified FTD cases suggesting that TMEM106B might have a general neuronal protection role in neurodegeneration apart from FTD.
This observation suggested that a potential involvement of TMEM106B in the endosome/lysosome pathway may play a role in neurodegenerative disorder risk or vulnerability.
Neuronal survival requires continuous lysosomal turnover of cellular contents through endocytosis and autophagy 72 . Impaired lysosomal function reduces lysosomal degradative efficiency, which leads to abnormal build-up of toxic components in the cell. Impaired lysosomal system has been found to be associated with a broad range of neurodegenerative disorders, 87 , inclusion body myositis 88 , and osteopetrosis 89 .
Considering the extensive involvements of lysosomal/endosomal compartments in neurodegenerative disorders, it has been proposed that a long and chronic process of abnormal metabolic changes during aging has led to the accumulation of toxic materials 72 . To conclude, we have identified a protective variant rs1990621 in TMEM106B associated with increased neuronal proportion through bulk RNA-Seq deconvolution and cell type proportion QTL analysis. This observation also replicated previous findings of the protective variant rs1990622 in FTD risk, which is in high LD with rs19990621 25 . Besides, we also observed the C allele of rs429358 (codetermine APOE e4 isoform with rs7412 C allele) associated with decreased neuronal proportion as it was hypothesized. It suggested potential involvements of both APOE and TMEM106B in neuronal protection mechanisms underlying neurodegenerative and normal aging processes, and supported previous observation of interactions between these two genes 61 in AD cohort. We speculate that TMEM106B related lysosomal changes might be involved in the common pathway underlying neuronal death and astrocytosis in neurodegenerative disorders and normal aging cohorts. With larger sample size and higher deconvolution resolution, this approach will reveal more biologically relevant and novel loci associated with changes in cellular composition that are important for understanding both disease etiology and healthy aging. RNA-Seq and paired genotype or WGS data were accessed and preprocessed for downstream analysis. Genotype data was censored based on our quality control criteria and imputed as needed. WGS and imputed genotype were merged and followed by PCA and IBD procedures to select unrelated European ancestry subjects. RNA-Seq data was quality checked with FastQC and aligned to human GRCh37 primary assembly with Star, from which TIN was inferred with RSeQC to account for RNA integrity variances that we later incorporated into the analysis. Gene expression were quantified from unaligned RNASeq with psedo-aligner Salmon for deconvolution procedure. Cell type composition comprised of four major CNS cell type proportions were inferred by performing deconvolution procedure on gene expression quantification results. Using cell type proportions as quantitative traits, we identified loci in TMEM106B gene region associated with neuronal proportion in our assembled dataset.
Figure 5 Discovery and replication phases Manhattan and QQ plots.
Loci located in chromosome 7 were associated with neuronal proportion in ROSMAP discovery dataset and replicated in replication dataset. A) Discovery set Manhattan plot showed seven peaks associated with neuronal proportion at suggestive threshold. The peak located in chromosome 7 was labeled, which is for rs1990621 with p-value = 6.4×10 -07 . B) QQ plot of the discovery phase analysis. C) Replication set Manhattan plot showed that the peak located in chromosome 7 replicated the signal identified during discovery phase with p-value = 7.41×10 -04 . D) QQ plot of the replication phase analysis. Summary random effect was depicted at the bottom as RE Summary. B) PM-Plot of rs1990621 while combining both p-value (y axis) and m-value (x axis). Red dot indicates that the variant is predicted to have an effect in that particular dataset, blue dot means that the variant is predicted to not have an effect, and green dot represents ambiguous prediction. C) Forest plot p-value and confidence interval for rs1990621 for discovery, replication, and merged datasets. D) Forest plot p-value and confidence interval for rs1990621 when splitting the merged dataset into four main disease categories. 
